Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AGN-214868 in Postherpetic Neuralgia
NCT01678924Phase 2Terminated
- Sponsor
- Allergan
- Start
- Jan 2013
- Primary completion
- May 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of senrebotase in postherpetic neuralgia (PHN), sponsored by Allergan. Started Jan 2013; status: terminated.
02
Drugs
senrebotase
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT01678924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678924.